TB-500 — the synthetic version of Thymosin Beta-4 (TB4) — is one of the most widely researched recovery peptides available. Canadian researchers studying tissue repair, inflammation, and systemic healing have increasingly turned to TB-500 as a research tool. This guide covers its mechanism, key research findings, and practical notes for sourcing verified TB-500 in Canada.
TB-500 is a synthetic fragment of the naturally occurring protein Thymosin Beta-4, a 43-amino acid peptide that is ubiquitously expressed in mammalian tissue. Thymosin Beta-4 was first identified in the thymus and was initially studied for its role in T-cell development, but subsequent research revealed a far broader range of biological activities — particularly in tissue repair and regeneration.
The synthetic version used in research (TB-500) corresponds to the actin-binding domain of the native protein. This fragment is believed to account for the majority of Thymosin Beta-4's regenerative activity in preclinical models. TB-500 is water-soluble and exhibits a relatively good stability profile compared to many other research peptides, making it a practical subject for laboratory investigation.
TB-500 is not approved by Health Canada for therapeutic use. VELTRIDE products are supplied strictly for in-vitro research and laboratory use. Not for human consumption.
TB-500's primary mechanism involves sequestration of actin monomers (G-actin) via its actin-binding domain. By modulating the availability of G-actin, TB-500 influences cytoskeletal dynamics in ways that appear to promote cell migration, proliferation, and differentiation in wound healing models. This actin-regulatory activity is thought to underlie many of its observed effects on tissue repair.
Beyond actin modulation, research has documented TB-500's ability to upregulate cell surface receptors involved in inflammation control, promote angiogenesis through endothelial cell migration, and reduce levels of inflammatory cytokines in various animal models. It also appears to exert effects on stem cell activation and homing, which has contributed to interest in its role in systemic healing protocols.
Preclinical studies using TB-500 have documented accelerated healing of tendon, ligament, skin, and muscle tissue in animal models. Research in cardiac tissue models has shown reduced fibrosis and improved functional recovery following experimental injury. In central nervous system models, TB-500 has been studied for its potential neuroprotective effects, with some studies reporting improved functional outcomes in models of neurological injury.
The systemic distribution of TB-500 — unlike many peptides that act primarily locally — makes it a particularly interesting research subject. Its apparent ability to travel to sites of injury and promote repair throughout the body has been documented in several rodent studies, and has contributed to interest in stacking it with locally-acting compounds like BPC-157 in recovery research protocols.
Many researchers combine TB-500 with BPC-157 in recovery protocols. The two peptides appear to operate through complementary mechanisms — BPC-157 works primarily through the nitric oxide pathway and local tissue protection, while TB-500 acts systemically through actin regulation and immune modulation. Together, they represent one of the most studied peptide combinations in preclinical recovery research.
VELTRIDE supplies both BPC-157 5mg and TB-500 5mg individually, and the Heal Fast Stack bundle combines both at a reduced price point for researchers working on combined protocols.
→ VIEW TB-500 AND BPC-157 IN THE VELTRIDE SHOPResearch-grade TB-500 should be ≥98% pure by HPLC, with a certificate of analysis from an independent third-party laboratory confirming both identity and purity. Domestic sourcing ensures consistent cold-chain protection during shipping — essential for peptide stability. VELTRIDE supplies TB-500 5mg for research use with full documentation and discreet, cold-chain protected shipping across BC and Canada.